Anagnostis Panagiotis, Rizos Christos V, Skoumas Ioannis, Rallidis Loukianos, Tziomalos Konstantinos, Skalidis Emmanuel, Kotsis Vasileios, Doumas Michalis, Kolovou Genovefa, Sfikas George, Garoufi Anastasia, Lambadiari Vaia, Dima Ioanna, Kiouri Estela, Agapakis Dimitrios, Zacharis Evangelos, Antza Christina, Kolovou Vana, Koumaras Charalambos, Bantouvakis George, Liamis George, Liberopoulos Evangelos N
Department of Endocrinology, Police Medical Centre of Thessaloniki, Thessaloniki, Greece.
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Endocrine. 2022 May;76(2):324-330. doi: 10.1007/s12020-022-03013-y. Epub 2022 Mar 9.
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) in the general population. However, such a role in patients with familial hypercholesterolemia (FH) is less documented. The purpose of this study was to evaluate the association between Lp(a) concentrations and ASCVD prevalence in adult patients with FH.
This was a cross-sectional study from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Patients were categorized into 3 tertiles according to Lp(a) levels.
A total of 541 adult patients (249 males) with possible/probable/definite FH heterozygous FH (HeFH) were included (mean age 48.5 ± 15.0 years at registration, 40.8 ± 15.9 years at diagnosis). Median (interquartile range) Lp(a) concentrations in the 1st, 2nd and 3rd Lp(a) tertile were 6.4 (3.0-9.7), 22.4 (16.0-29.1) and 77.0 (55.0-102.0) mg/dL, respectively. There was no difference in lipid profile across Lp(a) tertiles. The overall prevalence of ASCVD was 9.4% in the first, 16.1% in the second and 20.6% in the third tertile (p = 0.012 among tertiles). This was also the case for premature ASCVD, with prevalence rates of 8.5, 13.4 and 19.8%, respectively (p = 0.010 among tertiles). A trend for increasing prevalence of coronary artery disease (8.3, 12.2 and 16.1%, respectively; p = 0.076 among tertiles) was also observed. No difference in the prevalence of stroke and peripheral artery disease was found across tertiles.
Elevated Lp(a) concentrations are significantly associated with increased prevalence of ASCVD in patients with possible/probable/definite HeFH.
脂蛋白(a)[Lp(a)]是普通人群动脉粥样硬化性心血管疾病(ASCVD)的独立危险因素。然而,其在家族性高胆固醇血症(FH)患者中的作用鲜有文献记载。本研究旨在评估成年FH患者中Lp(a)浓度与ASCVD患病率之间的关联。
这是一项来自希腊家族性高胆固醇血症登记处(HELLAS-FH)的横断面研究。根据Lp(a)水平将患者分为3个三分位数组。
共纳入541例可能/很可能/确诊的FH杂合子FH(HeFH)成年患者(249例男性)(登记时平均年龄48.5±15.0岁,诊断时平均年龄40.8±15.9岁)。第1、2和3个Lp(a)三分位数组中Lp(a)浓度的中位数(四分位间距)分别为6.4(3.0 - 9.7)、22.4(16.0 - 29.1)和77.0(55.0 - 102.0)mg/dL。各Lp(a)三分位数组的血脂谱无差异。ASCVD的总体患病率在第一个三分位数组中为9.4%,第二个三分位数组中为16.1%,第三个三分位数组中为20.6%(三分位数组间p = 0.012)。早发性ASCVD情况也是如此,患病率分别为8.5%、13.4%和19,8%(三分位数组间p = 0.010)。还观察到冠状动脉疾病患病率呈上升趋势(分别为8.3%、12.2%和16.1%;三分位数组间p = 0.076)。各三分位数组中中风和外周动脉疾病的患病率无差异。结论:在可能/很可能/确诊的HeFH患者中,Lp(a)浓度升高与ASCVD患病率增加显著相关。